van Emmerik L C, Kuijper E J, Fijen C A, Dankert J, Thiel S
Department of Medical Microbiology, University of Amsterdam, The Netherlands.
Clin Exp Immunol. 1994 Sep;97(3):411-6. doi: 10.1111/j.1365-2249.1994.tb06103.x.
Mannan-binding protein (MBP), a calcium-dependent plasma lectin, may play a role in the innate defence against microorganisms. After binding to carbohydrate structures at the bacterial surface, MBP activates the classical pathway of the complement system. To investigate the binding capacity of MBP to various bacteria associated with meningitis, an assay was developed to study the binding of MBP to bacteria grown in a semisynthetic fluid culture medium. Salmonella montevideo (containing a mannose-rich lipopolysaccharide (LPS)), used as a positive control strain, showed binding of radiolabelled MBP at a level of 80% compared with binding of MBP to zymosan. Binding of labelled MBP to Salm. montevideo was time-dependent, temperature-dependent and saturable. The binding was inhibited by unlabelled MBP, by mannose and by N-acetyl-D-glucosamine. Among bacterial pathogens often found to cause meningitis, a wide range of MBP binding capacities could be determined. The encapsulated Neisseria meningitidis (representatives from 11 serogroups other than group A were included: n = 22), N. mucosa (n = 1), Haemophilus influenzae type b (n = 10) and Streptococcus agalactiae (n = 5) had a low MBP binding capacity of 21.7% (95% confidence interval (CI) 3.3-40.1%). Escherichia coli K1 (n = 11), Strep. suis (n = 5), Strep. pneumoniae (n = 10) and N. meningitidis serogroup A (n = 2) showed intermediate MBP binding capacity of 58.4% (95% CI 40.0-76.8%). A third group consisting of non-encapsulated Listeria monocytogenes (n = 11), non-encapsulated H. influenzae (n = 2), non-encapsulated N. meningitidis (n = 2), N. cinera (n = 1) and N. subflava (n = 1) strains had a high MBP binding capacity of 87.5% (95% CI 62.5-112.5%). The majority of encapsulated pathogens causing bacterial meningitis seem to have a rather low MBP binding capacity.
甘露聚糖结合蛋白（MBP）是一种钙依赖性血浆凝集素，可能在针对微生物的固有防御中发挥作用。MBP与细菌表面的碳水化合物结构结合后，会激活补体系统的经典途径。为了研究MBP与各种脑膜炎相关细菌的结合能力，开发了一种检测方法，以研究MBP与在半合成液体培养基中生长的细菌的结合情况。蒙得维的亚沙门氏菌（含有富含甘露糖的脂多糖（LPS））用作阳性对照菌株，与MBP与酵母聚糖的结合相比，放射性标记的MBP的结合水平为80%。标记的MBP与蒙得维的亚沙门氏菌的结合具有时间依赖性、温度依赖性且可饱和。未标记的MBP、甘露糖和N-乙酰-D-葡萄糖胺可抑制这种结合。在经常导致脑膜炎的细菌病原体中，可以确定广泛的MBP结合能力。包膜的脑膜炎奈瑟菌（包括A群以外11个血清群的代表菌株：n = 22）、粘膜奈瑟菌（n = 1）、b型流感嗜血杆菌（n = 10）和无乳链球菌（n = 5）的MBP结合能力较低，为21.7%（95%置信区间（CI）3.3 - 40.1%）。大肠杆菌K1（n = 11）、猪链球菌（n = 5）、肺炎链球菌（n = 10）和A群脑膜炎奈瑟菌（n = 2）的MBP结合能力中等，为58.4%（95% CI 40.0 - 76.8%）。第三组由非包膜的单核细胞增生李斯特菌（n = 11）、非包膜的流感嗜血杆菌（n = 2）、非包膜的脑膜炎奈瑟菌（n = 2）、灰色奈瑟菌（n = 1）和微黄奈瑟菌（n = 1）菌株组成，其MBP结合能力较高，为87.5%（95% CI 62.5 - 112.5%）。大多数导致细菌性脑膜炎的包膜病原体似乎具有相当低的MBP结合能力。
